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Abstract
Background: CCL21 acting through CCR7, is termed a homeostatic chemokine. Based on its role in concerting
immunological responses and its proposed involvement in tissue remodeling, we hypothesized that this chemokine could
play a role in myocardial remodeling during left ventricular (LV) pressure overload.
Methods and Results: Our main findings were: (i) Serum levels of CCL21 were markedly raised in patients with symptomatic
aortic stenosis (AS, n = 136) as compared with healthy controls (n = 20). (ii) A CCL21 level in the highest tertile was
independently associated with all-cause mortality in these patients. (iii) Immunostaining suggested the presence of CCR7 on
macrophages, endothelial cells and fibroblasts within calcified human aortic valves. (iv). Mice exposed to LV pressure
overload showed enhanced myocardial expression of CCL21 and CCR7 mRNA, and increased CCL21 protein levels. (v)
CCR72/2 mice subjected to three weeks of LV pressure overload had similar heart weights compared to wild type mice, but
increased LV dilatation and reduced wall thickness.
Conclusions: Our studies, combining experiments in clinical and experimental LV pressure overload, suggest that CCL21/
CCR7 interactions might be involved in the response to pressure overload secondary to AS.
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Introduction
Aortic stenosis (AS) leads to pressure overload, myocardial
hypertrophy and ultimately heart failure (HF) [1]. If left untreated,
the prognosis of symptomatic AS is poor with an average survival
of 2 years after onset of HF [2]. The disease progression in AS is
now considered an active process and shares both risk factors and
histopathological features with atherosclerosis, including lipopro-
tein accumulation, inflammation and remodeling of the extracel-
lular matrix [3–5].
The chemokines CCL21 and CCL19, acting through their
common receptor CCR7, are termed homeostatic due to their role
in immune surveillance and regulation of leukocyte movement
during homeostasis [6,7]. Recent studies suggest that CCR7 and
its ligands are also expressed in non-lymphoid cells such as
fibroblasts, vascular smooth muscle cells, and endothelial cells,
potentially being involved in vascular inflammation, cell prolifer-
ation, and matrix remodeling [8–10]. In line with this, the CCR7/
CCL19/CCL21 dyad has also been implicated in various
disorders characterized by inflammation and matrix remodeling
such as atherosclerosis, rheumatoid arthritis and inflammatory
bowel disease [9,11,12].
Recently, we demonstrated markedly increased myocardial
expression of CCL21 in both clinical and experimental post-
infarction HF, and we have also shown that increased serum levels
of CCL21 were associated with increased total mortality in
patients with acute and chronic HF [13]. Based on its essential role
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in concerting immunological and inflammatory responses, as well
as its newly discovered involvement in tissue remodeling possibly
including HF progression, we hypothesized that CCL21 could also
be associated with both progression and pathogenic consequences
of AS. Here, we elaborated this hypothesis by clinical studies on
the association between CCL21 levels and outcome in patients
with symptomatic AS. Additional studies looking for a potential
role for CCL21/CCR7 in left ventricular (LV) pressure overload-
induced remodeling were performed in an animal model of aortic
banding, including studies in CCR7 deficient mice.
Methods
Ethics Statement
The clinical part of this study was approved by the Regional
Health Authorities of South-Eastern Norway and conducted
according to the ethical guidelines outlined in the Declaration of
Helsinki for use of human tissue and subjects. Informed written
consent was obtained from all subjects. All animal experiments
were carried out in accordance with institutional guidelines, and
conform to the Guide for the Care and Use of Laboratory Animals
published by the US National Institutes of Health (NIH
Publication No. 85–23, revised 1996) and was approved by the
Norwegian National Animal Research Committee (permit of
approval number STFDU2796).
Patients and controls
A total of 136 patients with symptomatic AS, evaluated for
aortic valve replacement (AVR) between May 2005 and January
2007 at the Department of Cardiology, Oslo University Hospital
Rikshospitalet, were consecutively enrolled in the study (Table 1).
All AS patients were electively evaluated for symptomatic AS at
our hospital and were all in a stable clinical condition and on
optimal medical treatment. Only patients with confirmed AS as
assessed by echocardiography were included. Echocardiographic
parameters and blood samples were obtained from all patients.
Coronary angiography was performed in all patients to diagnose
the presence of concomitant coronary artery disease [CAD; i.e.
disease in at least one vessel (.50% narrowing of luminal
diameter)]. The exclusion criteria were severe (grade III) aortic or
mitral regurgitation or serum creatinine .150 mmol L21. All
examinations of the individual patients were conducted within a
period of a few days. Of the 136 patients, 108 were scheduled for
AVR, whereas surgical intervention was not performed in the
remaining 28 because of co-morbidity and/or estimated high
perioperative risk (n = 19), unwillingness of the patient to undergo
surgery (n = 4), or because clinical benefit was uncertain owing to a
mean aortic gradient ,35 mmHg (n = 5). Two patients amongst
those scheduled for AVR died pending surgery, thus 106 patients
underwent surgical intervention. Control subjects were 20 sex- and
age-matched apparently healthy individuals based on disease
history and clinical examination.
Aortic valve sampling
Aortic valve specimens were obtained from patients (n = 6)
undergoing elective AVR surgery. The valve cusps were excised as
seen fit by the operating surgeon. Comparative immunohisto-
chemical analyses were performed on aortic valves from persons
with no medical history or macroscopic signs of heart disease
(n = 4) obtained from autopsies. All aortic valve specimens were
immediately immersed in formalin.
Echocardiography
Doppler echocardiographic calculations of stroke volume and
cardiac output were performed on the basis of the cross-sectional
area of flow and aortic annular flow velocity data. Continuous
wave Doppler from multiple positions was used to obtain the
maximum aortic annular blood flow velocities, and used to
calculate aortic valve area by use of the continuity equation [14].
LV ejection fraction (LVEF) was obtained by the biplane Simpson
method [15]. In order to obtain a semiquantitative measure of the
morphology of the stenotic aortic valve, ultrasound backscatter
data analysis was performed as previously described [16].
Observers were blinded to the clinical patient status and the
standard echo findings.
Biochemistry and blood sampling
Peripheral venous blood was drawn into pyrogen-free tubes
with EDTA as anticoagulant. The tubes were immediately
immersed in melting ice and centrifuged within 30 minutes at
2000 g for 20 minutes to obtain platelet-poor plasma. All samples
were stored at 280uC and had been thawed once prior to assay.
N-terminal pro-brain natriuretic peptide (NT-proBNP) and C-
reactive protein (CRP) were assayed on a MODULAR platform
(Roche Diagnostics, Basel, Switzerland). Plasma levels of low-
density lipoprotein (LDL) cholesterol, high-density lipoprotein
(HDL) cholesterol and creatinine were measured enzymatically
using a Roche/Hitachi 917 analyser (Roche Diagnostics, Mann-
heim, Germany). Estimated glomerular filtration rate (eGFR) was
calculated according to the Modification of Diet in Renal Disease
(MDRN) formula. Troponin T (TnT) was measured by electro-
chemiluminescence immunoassay (hsTnT, Elecsys Troponin T
high sensitive, Roche Diagnostics). Plasma CCL21 levels were
measured by enzyme immunoassay (R&D Systems, Stillwater,
MN).
Immunohistochemistry
Sections of paraffin-embedded aortic valves were deparaffinised
and treated with 0.5% H2O2, followed by high-temperature
unmasking in citrate buffer (pH 6), blocked with 0.5% bovine
serum albumin (BSA) and then incubated with primary antibodies
against human CCR7 (polyclonal ab65851, abcam, Cambridge,
MA) for 1 hour at room temperature. After washing, the slides
were incubated for 30 minutes with peroxidase-conjugated
secondary antibody (Impress-Vector, Vector Laboratories, Bur-
lingame, CA), rinsed, and developed with chromogen for
immunoperoxidase staining (DAB Plus, Vector Laboratories) for
7 minutes. The sections were counterstained with hematoxylin.
Omission of the primary antibody was used as negative control.
The different cell types were identified under the microscope by a
professor of pathology using typical histological characteristics of
the actual cells.
Immunofluorescence
Five micron sections of paraffin-embedded mouse hearts were
deparaffinised in xylene, rehydrated in alcohol series and
immersed in distilled water, followed by high-temperature antigen
retrieval in citrate buffer (pH 6) and blocked with 0.5% bovine
serum albumin (BSA). For immunofluorescence, the slides were
stained with primary antibodies against CCR7 (NB110-55680,
Novus Biologicals, Littleton, CO; 1:100), CD31 (DIA-310,
Dianova GmbH, Hamburg, Germany; 1:100), Fibroblast Marker
(sc-73355, Santa Cruz Biotechnology, San Diego, CA; 1:100), a
smooth muscle Actin (ab7817, abcam, Cambridge, UK; 1:100) or
Mac2 (CL8942AP, Cedarlane, Burlington, Canada; 1:400) for
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1 hour at room temperature and counterstained with Alexa Fluor
488 goat anti-rabbit IgG (1:500), Alexa Fluor 568 goat anti-rat
IgG (1:500), Alexa Fluor 568 goat anti-mouse or Rat on Mouse AP
Polymer kit in combination with Warp Red Chromogen kit
(Biocare Medical, San Francisco, CA), respectively. The slides
were mounted with SlowFade Gold antifade reagent with DAPI
(Life Technologies, Carlsbad, CA). Images were taken by a Nikon
Eclipse E400 microscope (Tokyo, Japan).
Mouse model of experimental LV pressure overload
C57BL/6 mice were purchased from Møllergaard (Møller-
gaard, Denmark). The CCR72/2 mice were constructed at the
Max-Delbru¨ck-Center for Molecular Medicine (Berlin, Germany).
A 0.5 kb genomic fragment of the third exon of CCR7
encompassing Ser-139 to Asp-309 was disrupted by insertion of
the neomycin resistance gene. The herpes simplex thymidine
kinase gene was then fused to the 59 end. The CCR72/2 mice
were backcrossed for at least 8 generations onto the C57BL/6
background and bred at the Institute for Experimental Medical
Research, Oslo University Hospital Ulleva˚l, Oslo, Norway.
Banding of the ascending aorta was carried out in 7–8 week old
WT and CCR72/2 mice. Anaesthesia was induced with .5%
isoflurane gas and ,95% O2 in a gas chamber, followed by
tracheotomy and ventilation with 2% isoflurane and 98% O2, with
a tidal volume of 350 ml and a respiratory frequency of 160 min21
on a MiniVent ventilator (Harvard Apparatus, Holliston, MA). A
sternal split of the cranial 1/3 of the sternum was performed and
an 8–0 silk ligature was tied around the ascending aorta and a
blunted 26G needle, which was subsequently removed. Sham-
operated animals underwent the same procedure without banding
of the aorta. Three weeks after surgery, the animals were
anesthetized and ventilated before echocardiography was carried
out using a VEVO 2100 (Visualsonics, Toronto, Canada) as
previously described [17]. The animals were subsequently
euthanized and their hearts were removed and blotted dry. The
left ventricle, right ventricular free wall, and lungs were weighed
Table 1. Patient characteristics and association (Pearsson) with plasma CCL21 levels in 136 patients with symptomatic AS.
Total population CCL21
Age (yrs) 74610 0.59***
Male (%) 55 0.22*
BMI (kg/m2) 26.364.3 20.27**
CAD (%) 43 0.21*
Current smokers (%) 33 20.11
DM (%) 11 0.03
Hypertension (%) 25 0.05
Atrial fibrillation (%) 34 0.19*
Biochemistry
HDL cholesterol (mM){ 1.6 (1.3,1.9) 0.09
LDL cholesterol(mM) { 3.0 (2.4,3.9) 20.14
eGFR{ 66 (52,86) 0.66***
CRP (mg/L){ 1.9 (0.9,4.4) 0.09
hsTnT (mM) { 14.1 (8.3,25.0) (8.3,25.0) 0.40***
Medication (%)






NYHA functional class 4/40/75/1 0.19*
Hemodynamics
LVEF (%) 62612 20.14
CO (L/min){ 4.8 (4.2,5.6) 20.35***
Aortic valve area (cm2){ 0.62 (0.50,0.80) (0.50,0.80) 20.42***
Mean aortic gradient (mmHg) 53.5620.2 0.16
Backscatter (dB) 18.865.0 0.27**
Neurohormonal
NT-proBNP (pM){ 98 (42,279) 0.36***
Data are given as mean 6SD, {median (1. and 3. quartiles) or percentage of total number.
BMI, Body Mass Index; CAD, coronary artery disease; DM, Diabetes Mellitus; ARB, angiotensin receptor blocker; CO, cardiac output. To convert NT-proBNP values from
pM to pg/ml multiply by 8.47.
*p,0.05, **p,0.01, ***p,0.001.
doi:10.1371/journal.pone.0112172.t001
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and normalized to tibia length. Only mice with a maximum flow
velocity across the stricture .3.5 m/s three days after AB were
included.
Quantitative Real-Time RT-PCR
Total RNA from mouse left ventricle was extracted using
TRIzol (Invitrogen, San Diego, CA), DNase treated, cleaned up
using RNeasy Mini Columns (Qiagen, Hilden, Germany), and
stored at 280uC. cDNA was synthesized from 1 mg RNA using
High Capacity cDNA Archive Kit (Applied Biosystems, Foster
City, CA). Quantification of gene expression was performed using
the ABI Prism 7500 (Applied Biosystems), 5 ng cDNA, Power
SYBR Green Master Mix (Applied Biosystems), and sequence-
specific PCR primers were designed using the Primer Express
software, version 3.0 (Applied Biosystems). Primer sequences can
be provided on request. Gene expression of the housekeeping gene
GAPDH was used for normalization.
Western blotting
Total protein homogenates of LV from sham operated mice and
from mice with compensated and decompensated hypertrophy
due to aortic banding-induced pressure overload. Briefly, LV
tissue was homogenized in T-PER Tissue protein extraction
reagent (Thermo Scientific, Rockford; IL) supplemented with
protease and phosphate inhibitors (Halt Protease and Phosphatase
Inhibitor Cocktail; Thermo Scientific). The homogenates were
cleared by centrifugation and concentrations were measured using
the BCA assay (Bio-Rad, Hercules, CA). Protein homogenates
were separated under denaturing conditions on 4–20% SDS-
polyacrylamide gels (Mini-PROTEAN TGX Precast gels) and
electroblotted on to PVDF membranes (Thermo Scientific). The
membranes were blocked in Superblock T20/TBS (Thermo
Scientific) and incubated with 0.1 mg/ml (diluted in Superblock
T20/TBS) goat anti-mouse CCL21 antibody (AF457; R&D
Systems) and subsequently a horseradish peroxidase-conjugated
donkey anti-goat antibody (Santa Cruz Biotechnology, Santa
Cruz, CA). CCL21 expression was detected by chemilumines-
cence (SuperSignal West Pico; Thermo Scientific) and the C-Digit
Blot Scanner (Li-Cor). The membranes were stripped using
Restore Western Blot Stripping buffer (Thermo Scientific),
blocked and reprobed with 0.05 mg/ml mouse anti-GAPDH
antibody (G8795, Sigma-Aldrich). Densitometrical quantification
was performed using ImageJ (NIH).
Analysis of myocardial hydroxyproline contents
Quantitative analysis of tissue contents of hydroxyproline was
performed by HPLC using the AccQ-Fluor reagent kit (Waters
Corporation Milford, MA, USA) essentially as previously de-
scribed [18]. The relation of myocardial hydroxyproline contents
to myocardial collagen has previously been reported [19].
Zymography
Total protein homogenates (40 ug, n= 6) from WT and
CCR72/2 LV subjected to pressure-overload were mixed with
26non-reducing SDS-PAGE sample buffer and resolved through
a 10% Tris-Glycine gel with 0,1% gelatin (Novex Zymogram
Gelatin Gel, Invitrogen, San Diego, CA). After electrophoresis the
gels were first incubated in 100 mL Novex Zymogram Renaturing
Buffer and then in 100 mL Novex Zymogram Developing Buffer
(both Invitrogen, San Diego, CA) for 30 min under gentle
agitation at room temperature, before incubating overnight (20–
24 hours) in 100 mL Novex Zymogram Developing Buffer at
37uC. The gels were subsequently rinsed 365 minutes with
deionized water under gentle agitation at room temperature,
before they were stained in 20 mL SimplyBlue Safestain (Life
Technologies AS) for one hour at room temperature under gentle
agitation. Finally, the gels were rinsed 261 hour in deionized
water, scanned with a resolution of 300 dpi and saved as TIFF
images. Band intensities were measured using ImageJ (Wayne
Rasband, National Institute of Mental Health).
Statistical analysis
CCL21 levels between patients and controls were compared
with the Mann-Whitney U-test. If more than three groups were
compared, the Kruskal-Wallis test was used a priori. Associations
between CCL21 levels and clinical variables (Table 1) were
analyzed by linear regression on log transformed measures as
necessary determined by normality assessed by the Kolmogorov–
Smirnov test. The association of CCL21 with all-cause mortality
was investigated by receiver-operating characteristics (ROC) and
Kaplan–Meier analysis with log-rank test performed to compare
the number of events in different groups (comparisons pooled over
strata). Follow-up time for all-cause mortality was calculated from
time of inclusion to death from any cause. P values are two-sided
and considered significant when ,0.05. All analyses were
performed with SPSS for Windows version 15.0 (SPSS, Chicago,
IL).
Results
Circulating CCL21 levels in patients with AS and
associations with clinical features and myocardial
function
Figure 1A shows that plasma CCL21 levels were markedly
elevated in patients with symptomatic AS (n = 136) compared with
sex- and age-matched healthy controls (n = 20). The characteristics
of patients and their associations with CCL21 levels are shown in
Table 1. Several notable correlations were observed including
increasing CCL21 levels in relation to advancing age and
declining kidney function. Patients with high CCL21 levels were
also more likely to be males, to have accompanying CAD and
atrial fibrillation, to use ß-blockers and warfarin and to have a
lower body mass index (BMI). Although CCL21 was correlated
with the presence of CAD, raised CCL21 levels were also found
when these patients were excluded from the analyses (p,0.001
versus control, Figure 1B). Of relevance for increased LV outflow
obstruction and hypertrophy in AS, elevated CCL21 was also
associated with decreased aortic valve area and cardiac output as
well as with increased NT-proBNP and TnT as circulating
markers of hemodynamic burden and wall stretch, and myocyte
injury, respectively (Table 1 and Figure 1B). Including all the
above mentioned variables associated with CCL21 (i.e. age,
gender, BMI, CAD, atrial fibrillation, eGFR, TnT, b-blocker and
warfarin use, NYHA functional class, cardiac output, aortic valve
area, backscatter and NT-proBNP) in a stepwise regression
revealed that the strongest determinants of circulating CCL21
were (given as standardized coefficient, t and p-value) in
descending order: eGFR (Beta 20.49, t =26.11, p,0.001),
TnT (Beta 0.21, t = 2.78, p = 0.007), aortic valve area (Beta 2
0.17, t =22.29, p = 0.024) and backscatter (Beta = 0.14, t = 2.00,
p = 0.049) with an r square of 0.57 in the final model.
We have previously showed enhanced CCL21 levels in patients
with HF following MI. Although caution is needed when
comparing cytokine levels between different studies, AS patients
seem to have higher levels compared to the post-MI HF
population (median [25/75 percetile]; 224 [81,415] pg/ml VS.
360 [186,567] pg/ml, p,0.001, post-MI HF and AS patients,
The Chemokine CCL21 in Aortic Stenosis
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respectively). These data could possibly imply that the high levels
in AS do not merely reflect that these patients also have HF.
However, when dividing AS patients into LVEF below and above
40% we found that those with reduced LVEF were characterized
by increased CCL21 levels (median [25/75 percetile]; 339
[183,553] pg/ml VS. 553 [395,581] pg/ml, P = 0.022) suggesting
that the high CCL21 levels in AS patients, at least to some degree,
also are influenced by the degree of LV dysfunction in these
patients.
CCL21 is associated with all-cause mortality
During a median (Q1–Q3) follow-up of 4.6 (4.0,4.9) years, 35
patients died. CCL21 concentrations were significantly (p = 0.002)
higher in decedents (0.46 ng/mL [0.33,0.65]) than in survivors
(0.32 ng/mL [0.15,0.53]) and ROC analysis also demonstrated a
reasonable accuracy for the prediction of all-cause mortality at
follow-up (Figure 1C, left panel). This was confirmed in Kaplan-
Meier analyses demonstrating increased mortality with above
median levels of CCL21 (Figure 1C, right panel).
Increased CCR7 immunoreactivity in calcified aortic
valves
CCL21 mediates its effects through CCR7 and we therefore
analyzed the expression of CCR7 in aortic valves from six of the
patients with significant AS and 4 patients without AS (controls) by
means of immunohistochemistry. In AS patients, immunostaining
revealed significantly increased, although varying degrees, of
positive staining of macrophage-like cells as opposed to aortic
valves from control patients which did not reveal a significant
amount of CCR7 positive staining of these cells (Figure 2). CCR7
positive endothelial and fibroblast cells were found in valves from
both AS patients and controls. Despite considerable heterogeneity,
overall immunostaining showed increased presence of CCR7
within calcified aortic valves.
Myocardial CCL21 and CCR7 mRNA and CCL21 protein
expression is increased in experimental LV pressure
overload
Our findings so far suggested increased serum levels of CCL21
in symptomatic AS, which was significantly associated with
markers of impaired myocardial function, degree of AS and total
mortality during follow-up, and notably, an up-regulation of
CCR7 in aortic valves from AS patients. To further examine the
association between CCL21 and AS, we examined the myocardial
expression of CCL21 and CCR7 in an experimental model of
myocardial pressure overload (i.e., aorta banding, AB). As shown
in Figure 3A, we found a significant myocardial up-regulation of
CCL21 in hearts with compensated (n = 7) and in particular in de-
compensated (n = 7, significantly increased wet lung weight) LV
hypertrophy three weeks following AB as compared with sham
operated mice (n = 7). Furthermore, Western blotting showed a
stepwise increase in CCL21 protein levels, which was statistically
significant in the de-compensated hypertrophic heart (Figure 3B).
Myocardial expression of CCR7 mRNA was only increased
significantly in hearts with de-compensated hypertrophy (Fig-
ure 3C). CCR7 protein levels as assessed by Western blotting were
not detectable due to its low expression in murine hearts.
However, by using immunofluorescent staining of pressure-
overloaded hearts we demonstrated CCR7 expression in macro-
phages, smooth muscle cells and endothelial cells, while no
expression was seen in fibroblasts (Figure 4).
Figure 1. Circulating CCL21 levels in patients with AS and
associations with clinical features and myocardial function. (A)
Plasma levels of CCL21 in 136 patients with symptomatic aortic stenosis
compared to healthy controls (n = 20). (B) Plasma levels of CCL21 in the
aortic stenosis patients with and without coronary artery disease (CAD).
Data in A and B are shown as a box and whisker plot with median (Q1,
Q3) in the box and the whiskers representing the 5 and 95 percentile.
Outliers are shown as filled circles. (C) Scatter plots showing
associations between plasma CCL21 and aortic valve area, cardiac
output, N-terminal pro-brain natriuretic peptide (NT-proBNP) and
troponin T (TnT). (D) Association between plasma CCL21 and all-cause
mortality in patients with symptomatic aortic stenosis. Receiver-
operating characteristics curve analysis (area under the curve) for the
predictive value of CCL21(left panel) and Kaplan–Meier curves showing
the cumulative incidence of all-cause mortality according to median
CCL21 (low, high) levels at enrolment (right panel).
doi:10.1371/journal.pone.0112172.g001
Figure 2. Immunohistochemical staining for CCR7. Left panels (A
and B) show positive immunostaining of valves from patients with
symptomatic AS. Right panel (C) shows negative immunostaining of
valve from control. EC: Endothelial cells; M: Macrophage-like cells; FB:
Fibroblasts. Representative images obtained with640 objective. Scale
bar: 25 mm.
doi:10.1371/journal.pone.0112172.g002
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CCR72/2 mice display LV dilatation in response to
experimental LV pressure overload
As expected, WT mice developed myocardial hypertrophy with
significant increases in septum and LV posterior wall thickness as
assessed by echocardiography (Table 2), as well as increased LV
weight (Table 2) three weeks after AB. AB resulted in a similar
increase in LV weight in CCR72/2 mice. However the CCR7
deficient mice displayed ventricular dilation in response to
pressure overload, reflected in larger LV diameters, significantly
thinner septum and posterior walls, as well as lower calculated
relative wall thickness (Table 2). There were no significant changes
in wet lung weights following AB in either genotype (Table 2)
indicating compensatory hypertrophy in both genotypes. Howev-
er, there was a tendency towards reduced fractional shortening in
CCR72/2 mice indicating mildly worsened cardiac function
(Table 2).
WT and CCR72/2 mice demonstrate similar myocardial
collagen content, as well as MMP-2 and MMP-9 activity
following pressure overload
In search of underlying mechanisms for the increased dilatation
observed in CCR72/2 mice following AB, myocardial collagen
content was measured by means of quantitative analysis of
hydroxyproline. As shown in Figure 5A, a similar and significant
increase in collagen content was seen following pressure-overload
in both genotypes. Furthermore, no significant difference in
myocardial MMP-2 activity was detected on zymography 3 weeks
after AB, when comparing the two genotypes (Figure 5B). MMP-9
activity was not detectable on zymography for either genotype.
Figure 3. Myocardial CCL21 and CCR7 mRNA and CCL21
protein expression in experimental LV pressure overload. Left
ventricular expression of (A) CCL21 mRNA, (B) CCL21 protein levels and
(C) CCR7 mRNA in mice with compensated (n = 7) and de-compensated
(n = 7) hypertrophy three weeks after aortic banding, compared to
sham operated mice (n = 7). mRNA levels were quantified by real-time
RT-PCR and are presented relative to the gene expression of GAPDH.
CCL21 protein levels were quantified by Western blotting. Data are
mean6SEM. *p,0.05, **p,0.01 and ***p,0.001 vs. controls/sham.
doi:10.1371/journal.pone.0112172.g003
Figure 4. Immunofluoresence staining for CCR7. Presence of
CCR7 on (A) macrophages, (B) smooth muscle cells, (C) endothelial
cells, and not on (D) fibroblasts. Representative images obtained with
640 objective. Scale bar: 50 mm.
doi:10.1371/journal.pone.0112172.g004
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Discussion
CCR7 and its ligands have previously been related to various
inflammatory disorders including atherosclerosis and have also
been linked to development of HF [9,12,20]. Our present data
suggest that this chemokine system also could be involved in the
progression of AS and myocardial remodeling in response to
pressure overload. For the CCR7 ligand CCL21, markedly
enhanced expression was found systemically in patients with
symptomatic AS, and high serum levels of CCL21 were associated
with increased mortality in these patients. Moreover, increased
CCR7 immunoreactivities were found in calcified aortic valves
from patients undergoing AVR surgery. Finally, our studies in
CCR72/2 mice showed increased LV dilation in response to three
weeks of pressure overload, indicating a role for CCL21/CCR7 in
preserving LV geometry during cardiac stress.
The present study is, to the best of our knowledge, the first
report of elevated serum levels of homeostatic chemokines in
patients with symptomatic AS. We have previously shown
increased CCL21 levels in CAD [9] and in acute and chronic
post-infarction HF [13]. One could claim that the raised CCL21
levels in AS patients might merely reflect the presence of
accompanying CAD and HF in these patients. However, raised
CCL21 levels were also found when patients with CAD were
excluded from the analyses. Moreover, although patients with the
lowest LVEF had the highest CCL21 levels, suggesting some
influence of LV dysfunction on CCL21 levels, the high levels in AS
patients as compared with our previous data on CCL21 levels in
post-MI HF [13], suggest that the raised levels of CCL21 in AS
patients do not merely reflect accompanying HF. There was a
significant association between CCL21 and backscatter as a
marker of aortic valve calcification, and in particular with
decreased aortic valve area. In fact, CCL21 was significantly
associated with aortic valve area and backscatter also after
correction for several confounders. Moreover, in the experimental
model of pressure overload following AB, myocardial CCL21
mRNA expression was significantly increased in both compensat-
ed and decompensated hypertrophy, and CCL21 protein levels
were significantly increased in hearts with overt HF. These
findings suggest that CCL21 might have a role in the remodeling
process secondary to pressure overload and not merely reflect
associated conditions in these patients.
CCL21 seems primarily to be produced by stromal cells [6]. It is
possible that the ability of CCL21 to predict mortality may reflect
its regulation in stromal-related cells within the myocardium. In
the present study we found enhanced myocardial expression of
CCL21 and CCR7 during experimental pressure overload and
increased expression of CCR7 within aortic valves of AS patients.
While these data show a myocardial up-regulation of CCL21 and
CCR7 mRNA, as well as CCL21 protein levels during LV
pressure overload, the pathogenic significance of this finding is
unclear. Increased CCL21 levels have been reported in athero-
Table 2. Animal characteristics and echocardiographic measurements 3 weeks after sham operation or aortic banding.
Sham-Wt Sham-CCR72/2 AB-Wt AB-CCR72/2
(n = 6–7) (n =6–8) (n =7–8) (n =10–11)
Characteristics
BW, g 25.861.0 24.060.7 25.161.1 24.960.5
TL, mm 16.960.2 16.660.1 16.660.2 16.660.1
LVW/TL, mg/mm 4.9160.09 4.7360.52 7.3960.20* 7.4361.10*
RVW/TL, mg/mm 1.2360.07 1,3560.06 1.3660.06 1.5260.14
LW/TL, mg/mm 8.4860.20 8.8560.18 12.6261.40* 12.8462.20
Echo-MM
IVSd/TL 0.0560.00 0.0660.00 0.0860.00* 0.0760.00*{
LVDd/TL 0.2160.00 0.2460.01 0.2060.01 0.2660.01{
PWd/TL 0.0660.00 0.0660.00 0.0860.00* 0.0760.00*{
LVFS, % 2262 2562 2762 2062
LAD/TL 0.0860.00 0.0860.01 0.1060.01* 0.1260.01*
Echo-Doppler
HR, beats/min 383615 403621 409642 440636
Mit Vmax, m/s 0.3960.03 0.4460.03 0.5060.04 0.5360.03
Mit dec, m/s2 15.961.1 17.661.6 28.2565.19* 29.8662.72
AB Vmax, m/s 4.5360.23 4.6260.23
LVOT Vmax, m/s 1.1260.07 1.5161.13
{ 1.0360.11 1.0660.05*
LVOT VTI, cm 5.160.3 6.0460.4 4.9160.71 5.0560.47
CO, ml/min 20.661.4 30.663.7{ 28.866.4 30.164.1
Sham, sham operated group; AB, aorta banding group; WT, wild-type mice; CCR72/2, CCR7 knock-out mice; BW, body weight; TL, tibia- length; LVW/TL, left ventricular
weight normalized to TL; RVW/TL, right ventricular weight normalized to TL; LW/TL, lung weight normalized to TL; Echo-MM, M-mode echocardiography; IVSd/TL,
interventricular septum thickness in diastole normalized to TL; LVDd/TL, left ventricular diameter in diastole normalized to TL; PWd/TL, posterior wall thickness in
diastole normalized to TL; LVFS, left ventricular fractional shortening; LAD/TL, left atrial diameter normalized to TL; HR, heart rate; Mit Vmax, peak mitral flow; Mit dec,
mitral deceleration velocity; AB Vmax, peak flow through aortic banding; LVOT Vmax, peak left ventricular outflow tract flow; VTI, velocity time integral; CO, cardiac
output;
*p,0.05 vs sham in respective genotype group and {p,0.05 vs Wt in same group. Values are means 6 SEM.
doi:10.1371/journal.pone.0112172.t002
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sclerosis both systemically and within the lesion [9], but whether
this represents a pathogenic inflammatory response or compen-
satory beneficial mechanisms leading to enhanced exit of
leukocytes from the lesion is still unclear. Herein we found that
although CCR7 deficient mice exposed to AB showed only a mild
degree of impaired myocardial function, these mice exhibited LV
dilation, suggesting an impaired adaptive response to pressure
overload in these mice. Although we were unable to demonstrate
altered myocardial collagen content and MMP-2 and -9 activity
three weeks after aortic banding, it is possible that this might be
present at an earlier time-point, at least partly explaining the
increased dilation seen in CCR72/2 mice. We have previously
reported myocardial dilatation in CXCR52/2 mice following AB
indicating a role in adaptive remodeling for the homeostatic
chemokine CXCL13 [21]. It is possible that a similar effect could
be attributed to CCL21/CCR7 interaction. However, although
CCL21 has been implicated in beneficial remodeling processes
within the kidney [22], the role of CCL21/CCR7 interaction in
myocardial remodeling following LV pressure overload is at
present unclear.
The current study has some limitations such as the inclusion of
relatively few patients, and in particular controls. We also lack data
in patients with asymptomatic AS. Moreover, the changes in
echocardiographic variables in the CCR7 deficient mice were
rather modest and we lack data on the molecular mechanisms for
these findings. Furthermore, we were unable to carry out
immunofluorescent staining for CCL21 in hypertrophied murine
myocardium and to confirm the cellular localization of CCR7 in
calcified human aortic valves by co-staining with relevant
antibodies. Also, the lack of myocardial samples from different
time points hampered the ability to elucidate the mechanisms
underlying our findings in the experimental part of the study.
Nonetheless, our studies, combining experiments in clinical and
experimental LV pressure overload, suggest that CCL21/CCR7
interactions might be involved in the response to pressure overload
secondary to AS.
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